Arnold_ATTAIN_NEDA_TAND_Supp_Materials_032918_clean – Supplemental material for Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Supplemental material, Arnold_ATTAIN_NEDA_TAND_Supp_Materials_032918_clean for Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis by Douglas L. Arnold, Shulian Shang, Qunming Dong, Matthias Meergans and Maria L. Naylor in Therapeutic Advances in Neurological Disorders